This guidance updates and replaces NICE technology appraisal 3 (published in May 2000)

This guidance has been partially updated by NICE technology appraisal 91 (published May 2005)(review)

Recommendations 1.3, 1.4 and 1.5 of TA55 on re-challenge therapy and the second-line treatment of advanced ovarian cancer have been replaced. The recommendations for first-line treatment still stand.

  • Review update
    For further information regarding this, please see the 'Review update on the use of paclitaxel (1st line only) in the treatment of ovarian cancer' document under 'Background information'.

  • Get involved